Sulfonylureas Drug-Drug Interaction Table: Complete Prescriber Reference

What Is the Sulfonylurea Drug Class?

Sulfonylureas are oral insulin secretagogues that close ATP-sensitive potassium (K-ATP) channels on pancreatic beta cells, triggering calcium influx and insulin release independent of ambient glucose. The FDA first approved tolbutamide (first-generation) in 1957; second-generation agents, glipizide (1984), glyburide (1984), and glimepiride (1995), dominate contemporary prescribing because of improved receptor selectivity and lower hypoglycemia burden relative to first-generation agents [1].

The ADA 2024 Standards of Medical Care in Diabetes notes that sulfonylureas remain "effective, low-cost options" but carry a "well-recognized risk of hypoglycemia" that demands attention to interacting drugs and patient-specific factors [2].

Mechanism and Receptor Pharmacology

All sulfonylureas bind the sulfonylurea receptor 1 (SUR1) subunit of the K-ATP channel complex (SUR1/Kir6.2) on beta cells. Second-generation agents bind with roughly 100-fold greater affinity than first-generation agents, enabling lower milligram doses. Glimepiride also shows partial binding to cardiac SUR2A at therapeutic concentrations, a distinction that may explain its modest cardiovascular signal differences in observational data [3].

Pharmacokinetic Profiles Relevant to DDIs

Understanding which enzyme handles each agent is non-negotiable before adding any interacting drug:

| Agent | Primary Enzyme | Active Metabolite | Half-life | Renal Dose Adjustment | |---|---|---|---|---| | Glipizide | CYP2C9 | No | 2 to 4 h | Not required (inactive metabolites) | | Glyburide | CYP2C9, CYP3A4 | Yes (4-trans-hydroxy) | 10 h | Avoid eGFR <30 mL/min/1.73m² | | Glimepiride | CYP2C9 | Yes (M1, M2) | 5 to 9 h | Start 1 mg; titrate cautiously in CKD |

Glipizide's lack of active metabolites makes it the preferred agent in moderate chronic kidney disease (CKD stages 3 to 4) [4]. Glyburide's active metabolite accumulates when eGFR falls below 50 mL/min/1.73m², and the Beers Criteria 2023 lists glyburide as a drug to avoid in older adults for this reason [5].

Sulfonylurea Drug-Drug Interaction Table

The table below covers interactions with clinical evidence or plausible pharmacokinetic rationale. Severity ratings follow the standard three-tier system: Major (avoid or use only if no alternative), Moderate (monitor closely, consider dose adjustment), Minor (awareness sufficient).

CYP2C9 Inhibitors: Highest-Risk Category

CYP2C9 inhibition raises sulfonylurea area-under-the-curve (AUC) and prolongs half-life, directly increasing hypoglycemia risk. Fluconazole is the most studied offender. A crossover pharmacokinetic study (N=12 healthy volunteers) found that fluconazole 200 mg/day for 4 days increased glipizide AUC by 56% and Cmax by 20%, with corresponding reductions in blood glucose [6].

| Interacting Drug | Mechanism | Severity | Clinical Effect | Management | |---|---|---|---|---| | Fluconazole | CYP2C9 inhibition | Major | Glipizide AUC +56%; hypoglycemia risk increased | Avoid; if unavoidable, halve SU dose and monitor glucose daily | | Fluconazole | CYP2C9 inhibition | Major | Glimepiride AUC increases ~2-fold | Same; consider glucose log for full fluconazole course | | Miconazole (oral/topical systemic) | CYP2C9 inhibition | Major | Severe hypoglycemia case reports | Prefer topical nystatin if feasible | | Voriconazole | CYP2C9 + CYP3A4 inhibition | Major | Expected AUC increase; limited human data | Monitor glucose twice daily; dose reduction likely needed | | Amiodarone | CYP2C9 inhibition (weak-moderate) | Moderate | Gradual SU accumulation over weeks | Increase SMBG frequency; HbA1c may underestimate hypoglycemia burden | | Trimethoprim (alone or TMP-SMX) | CYP2C9 inhibition + renal OCT secretion blockade | Moderate | Glipizide and glimepiride AUC rise; effect onset within 24 to 48 h | Check glucose on day 2 to 3 of antibiotic course | | Metronidazole | CYP2C9 inhibition | Moderate | Case reports of hypoglycemia with glyburide | Monitor glucose; short courses (7 days) are usually manageable | | Sulfonamide antibiotics | CYP2C9 inhibition + protein displacement | Moderate | Combined PK and PD potentiation | Monitor closely; historical reports of severe events | | Clopidogrel (active metabolite) | CYP2C9 inhibition | Moderate | Modest AUC increase; clinical impact depends on SU dose | Routine glucose monitoring; adjust SU if HbA1c drifts low |

CYP2C9 Inducers: Loss of Glycemic Control

CYP2C9 inducers accelerate sulfonylurea clearance, shrinking exposure and impairing postprandial glycemic control. The interaction is often under-recognized because the clinical presentation is rising HbA1c rather than an acute event [7].

| Interacting Drug | Mechanism | Severity | Clinical Effect | Management | |---|---|---|---|---| | Rifampin (rifampicin) | Strong CYP2C9 induction | Major | Glipizide AUC reduced by up to 70% | Avoid concurrent use; if unavoidable, titrate SU up by 50 to 100% with close monitoring | | Carbamazepine | CYP2C9 + CYP3A4 induction | Moderate | Reduced SU exposure; hyperglycemia risk | Check HbA1c at 6 weeks after adding or stopping | | Phenytoin / fosphenytoin | CYP2C9 induction | Moderate | Reduced glimepiride exposure expected | Monitor HbA1c; dose SU to effect | | Phenobarbital / primidone | CYP2C9 induction | Moderate | Historical data for first-generation SU; class effect assumed | As above | | St. John's Wort | CYP2C9 + P-gp induction | Moderate | Reduced SU levels; over-the-counter use often undisclosed | Counsel patients to disclose all herbals at every visit | | Bosentan | CYP2C9 induction | Minor-Moderate | Modest reduction in SU exposure | Increased HbA1c monitoring during bosentan therapy |

Pharmacodynamic Potentiators: Hypoglycemia Without PK Change

These agents do not alter sulfonylurea plasma levels but lower blood glucose independently or impair counterregulation, compounding hypoglycemia severity [8].

| Interacting Drug | Mechanism | Severity | Clinical Effect | Management | |---|---|---|---|---| | Insulin | Additive insulin effect | Major | Severe hypoglycemia if combined without dose reduction | Rare combination; if used, reduce SU by 50% and titrate insulin carefully | | Other secretagogues (meglitinides) | Additive K-ATP channel closure | Major | No additive glycemic benefit; duplicated mechanism | Avoid combination; ADA 2024 does not recommend concurrent use | | GLP-1 receptor agonists | Glucose-dependent insulin amplification | Moderate | GLP-1-mediated insulin augmentation + SU effect; hypoglycemia at lower glucose thresholds | Reduce SU by 50% when initiating GLP-1 RA per ADA 2024 guidance [2] | | SGLT2 inhibitors | Glucosuria reduces baseline glucose | Moderate | Increased hypoglycemia risk particularly with glyburide | Consider SU dose reduction of 25 to 50% at SGLT2i initiation | | DPP-4 inhibitors | Incretin-mediated insulin release | Moderate | Additive secretagogue effect; real-world hypoglycemia rates rise modestly | Monitor; ADA notes the combination is guideline-acceptable with monitoring | | Alcohol (acute ingestion) | Gluconeogenesis inhibition | Moderate | Delayed hypoglycemia 3 to 36 h post-ingestion; particularly dangerous overnight | Counsel patients: eat carbohydrate with alcohol; consider lower SU dose in heavy drinkers | | Salicylates (high-dose, greater than 3 g/day) | Direct hypoglycemic effect + protein displacement | Moderate | Enhanced glucose lowering; aspirin 81 mg is not clinically significant | Low-dose aspirin is safe; rheumatologic doses warrant SMBG increase | | Fluoroquinolones | Dysregulated K-ATP channel closure | Moderate | Both hypoglycemia (predominant with gatifloxacin) and hyperglycemia reported; class varies | Prefer alternatives when feasible; monitor glucose at 48 h | | Pentamidine | Toxic beta-cell effect | Major | Acute hypoglycemia (insulin release) followed by hyperglycemia (beta-cell destruction) | Discontinue SU during pentamidine courses | | Quinine / quinidine | Stimulates insulin secretion | Moderate | Hypoglycemia reported in malaria treatment context | Monitor glucose daily during antimalarial course |

Pharmacodynamic Antagonists: Loss of Glycemic Control

| Interacting Drug | Mechanism | Severity | Clinical Effect | Management | |---|---|---|---|---| | Corticosteroids | Counter-regulatory hormone increase + insulin resistance | Moderate-Major | Postprandial hyperglycemia; HbA1c may underestimate burden with episodic steroid use | Up-titrate SU or add basal insulin during steroid course; taper SU after | | Thiazide diuretics (high-dose) | Hypokalemia impairs beta-cell secretion; insulin resistance | Minor-Moderate | Modest glucose elevation; effect is dose-dependent | Hydrochlorothiazide 12.5 to 25 mg has minimal impact; higher doses warrant monitoring | | Loop diuretics (high-dose) | Same mechanism as thiazides | Minor | Less evidence than thiazides; caution in high doses | Routine glucose monitoring | | Atypical antipsychotics | Insulin resistance + weight gain | Moderate | Clozapine and olanzapine carry highest risk; quetiapine moderate | Check HbA1c at 3 months after antipsychotic initiation | | Sympathomimetics (epinephrine, pseudoephedrine) | Catecholamine-mediated glycogenolysis | Minor | Transient glucose elevation | OTC decongestant doses are clinically low-impact in most patients |

Beta-Blockers: A Special Case

Beta-blockers deserve their own section because the interaction is pharmacodynamic but operates through a dual mechanism. First, beta-blockade (especially non-selective agents like propranolol) blunts the adrenergic warning symptoms of hypoglycemia (tremor, palpitations, anxiety) while preserving only sweating as a reliable symptom [9]. Second, non-selective beta-blockers impair hepatic glycogenolysis, extending hypoglycemia duration. Selective beta-1 blockers (metoprolol, atenolol, bisoprolol) carry a lower but non-zero risk, since selectivity is lost at higher doses.

| Agent | Selectivity | Symptom Masking | Glycogenolysis Impairment | Recommendation | |---|---|---|---|---| | Propranolol | Non-selective | Severe | Yes | Avoid with SU if alternatives exist; if used, patient education on sweat as sole warning | | Carvedilol | Alpha + beta (non-selective) | Moderate-severe | Partial | Same precautions as propranolol | | Metoprolol | Beta-1 selective | Moderate | Minimal | Acceptable; counsel on symptom masking | | Bisoprolol | Beta-1 selective | Moderate | Minimal | Preferred if beta-blocker required | | Atenolol | Beta-1 selective | Moderate | Minimal | Acceptable; monitor glucose at initiation |

Protein Binding and Displacement Interactions

All three major sulfonylureas are greater than 95% protein-bound (primarily albumin). Drugs that displace them from albumin can transiently raise free-fraction plasma concentrations, though modern pharmacokinetic theory holds that displacement alone rarely sustains clinically significant interactions because clearance increases proportionally [10]. The exception is when displacement co-occurs with CYP2C9 inhibition, as seen historically with sulfonamide antibiotics.

Highly protein-bound drugs that have historically been cited as displacement risks include warfarin, NSAIDs, fibrates (gemfibrozil in particular), and salicylates. Of these, gemfibrozil warrants the closest attention: it inhibits CYP2C8 and may partially inhibit CYP2C9, and case reports link it to severe hypoglycemia with repaglinide (a related secretagogue); data specific to sulfonylureas are limited but the biologic plausibility is high [11].

Renal and Hepatic Impairment as DDI Modifiers

Organ impairment changes the DDI risk field in ways that a flat interaction table cannot fully convey.

Renal Impairment

Reduced eGFR shrinks the safety margin for any CYP2C9 inhibitor added to glyburide or glimepiride because active metabolites accumulate independently. A patient on glimepiride with eGFR 35 mL/min/1.73m² who starts fluconazole for a vaginal candidiasis episode faces a multiplicative, not additive, hypoglycemia risk. The FDA label for glimepiride recommends starting at 1 mg/day in renal impairment and titrating cautiously [12].

Hepatic Impairment

CYP2C9 is predominantly hepatic. Any hepatic impairment (Child-Pugh B or C) reduces enzyme activity, effectively mimicking CYP2C9 inhibition even without a co-precipitant drug. Adding a true CYP2C9 inhibitor in Child-Pugh B hepatic impairment may raise sulfonylurea AUC to levels seen only at toxic doses in healthy volunteers. Prescribers should avoid sulfonylureas in Child-Pugh C disease and monitor closely in Child-Pugh B [4].

Pharmacogenomics: CYP2C9 Poor Metabolizers

Roughly 3 to 5% of European-ancestry patients carry two loss-of-function CYP2C9 alleles (CYP2C9*3/*3 or *2/3), making them phenotypic poor metabolizers. A pharmacogenomic study (N=62) found that CYP2C93 carriers had glipizide AUC values approximately 2.6-fold higher than wild-type subjects [13]. In a CYP2C9 poor metabolizer, even a "minor" CYP2C9 inhibitor (e.g., cimetidine) could push plasma concentrations to toxic levels. The Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for sulfonylureas and CYP2C9 recommends a 25 to 50% starting-dose reduction in poor metabolizers and avoiding strong CYP2C9 inhibitors entirely in this population [14].

HealthRX CYP2C9 Risk Stratification Framework for Sulfonylurea Prescribing:

1. Order CYP2C9 genotype before initiating a sulfonylurea in patients with a personal or family history of severe unexplained hypoglycemia.
2. Classify each co-prescribed drug as inhibitor (major/moderate/minor), inducer, or neutral.
3. Assign a baseline organ-function modifier (CKD stage, Child-Pugh class).
4. If inhibitor is major AND patient is CKD stage 3+ or poor metabolizer, either avoid the combination or halve the sulfonylurea dose and arrange glucose checks on days 2 and 5 of the precipitant drug.
5. If inducer is strong (rifampin, carbamazepine), plan HbA1c at 6 weeks post-initiation and again 6 weeks after discontinuation.

Alcohol and Lifestyle Interactions

Alcohol interacts with sulfonylureas through two distinct mechanisms. Acute heavy ingestion inhibits hepatic gluconeogenesis, extending hypoglycemia duration and shifting its nadir to 6 to 36 hours after the last drink, when the patient may be asleep and unable to recognize symptoms [15]. A fasting state worsens this interaction substantially.

Chronic heavy alcohol use induces CYP2C9 and CYP3A4, potentially reducing sulfonylurea exposure and blunting glycemic control over time. Both directions of alcohol-SU interaction can coexist in the same patient depending on drinking pattern. Prescribers should ask about binge versus chronic use separately at each visit.

Monitoring Protocol for High-Risk DDI Combinations

The following monitoring schedule applies when a CYP2C9 inhibitor of moderate-to-major severity is added to any sulfonylurea:

• Day 1 to 2: Patient performs fasting and 2-hour post-prandial glucose checks.
• Day 3 to 5: Review glucose log by phone or patient portal message.
• Week 2: Follow-up HbA1c not yet reflective; continue SMBG twice daily.
• Week 4: If course of precipitant drug is complete, re-check glucose pattern and consider returning to original SU dose.
• Week 12: HbA1c to confirm no chronic effect.

For CYP2C9 inducers added to a sulfonylurea, check HbA1c at 6 weeks and again 6 weeks after stopping the inducer, because enzyme induction and de-induction are slow processes (days to weeks) [7].

Key Counseling Points for Patients on Sulfonylureas

Prescribers should ensure patients understand the following before any new drug is added:

• Any new prescription, OTC drug, or supplement should be reported to their pharmacist or provider before starting.
• Signs of hypoglycemia include shakiness, sweating, confusion, and palpitations; patients on non-selective beta-blockers may experience only sweating.
• Alcohol consumption should be accompanied by a carbohydrate-containing meal.
• Skipping meals while continuing a full sulfonylurea dose is a significant hypoglycemia risk, independent of drug interactions.
• The ADA recommends structured diabetes self-management education (DSME) for all patients initiating pharmacotherapy [2].

Comparing Sulfonylurea DDI Risk Across Agents

Glipizide carries the lowest DDI risk of the three major agents for several reasons: it has no active metabolites, a short half-life (2 to 4 hours), and exclusively hepatic metabolism with inactive renal excretion products. When a CYP2C9-interacting drug must be used and the sulfonylurea cannot be discontinued, glipizide is the preferred agent to continue [4].

Glyburide carries the highest risk profile: it has active metabolites, a longer effective duration, partial CYP3A4 metabolism (meaning some CYP3A4 inhibitors also increase exposure), and active renal metabolite excretion that makes renal impairment a compounding variable.

Glimepiride sits between the two. Its active metabolites (M1 and M2) retain roughly 33% of the parent compound's hypoglycemic potency. CYP2C9 inhibition raises not just glimepiride but also M1 and M2 levels, compounding the pharmacodynamic effect.